Abeona Therapeutics® has announced that UTMB is New Qualified Treatment Center for ZEVASKYN® in Texas.
ZEVASKYN (prademagene zamikeracel) is a FDA-approved autologous gene therapy that is indicated for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). UTMB Dermatology Assistant Professors Drs. A. Munoz and L. Ross, along with Nurse Manager Jennifer Tribble, MSN, RN were instrumental in getting this new therapy available in Galveston.